Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17606328 | 1.00 | CA12 (0.31) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL30268847 | 1.00 | CA12 (0.31) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL17605558 | 1.00 | CA12 (0.31) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL17168952 | 1.00 | CA12 (0.31) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL17606329 | 1.00 | CA12 (0.31) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL15816597 | 1.00 | CA12 (0.31) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL30238647 | 0.96 | CA12 (0.34) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL30268841 | 0.96 | CA12 (0.34) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL15663044 | 0.96 | CA12 (0.34) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL15663045 | 0.96 | CA12 (0.34) | CA12CA1CA2MMP2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935263-B1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME (US) | 2018-12-05 | — | — | EP | disclosed |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2018-07-12 | — | — | US | disclosed |
| EP-2951180-B1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME (US) | 2018-05-02 | — | — | EP | disclosed |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| EP-2934535-B1 | SUBSTITUTED PYRROLOPYRIMIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9682978-B2 | 2,6,7 substituted purines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9637493-B2 | Substituted pyrrolopyrimidines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9540377-B2 | 2,6,7,8 substituted purines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2016044770-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| EP-2935263-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2934535-A2 | SUBSTITUTED PYRROLOPYRIMIDINES AS HDM2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-8962611-B2 | Substituted imidazopyridines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140357618-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME LLC | 2014-12-04 | — | — | US | disclosed |
| US-8846657-B2 | Substituted imidazopyridines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2014123882-A1 | 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-14 | — | — | WO | disclosed |
| WO-2014120748-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014100071-A2 | SUBSTITUTED PYRROLOPYRIMIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100065-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140179680-A1 | Substituted Imidazopyridines as HDM2 Inhibitors | MERCK SHARP & DOHME LLC | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | CA12 2687/4885CA1 2138/4885CA2 2250/4885 |
| US-20140179680-A1 | Substituted Imidazopyridines as HDM2 Inhibitors | DDX21, ING2, MDM2 | CA12 3301/4885CA1 2889/4885CA2 1792/4885 |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, KAT2A | CA12 2610/4885CA1 2016/4885CA2 2193/4885 |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | CA12 2687/4885CA1 2138/4885CA2 2250/4885 |
| US-20140357618-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | DDX21, ING2, MDM2 | CA12 3301/4885CA1 2889/4885CA2 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.